文献速递其他结缔组织病

可溶性SIGLEC1作为特发性炎性肌病疾病活动度生物标志物

Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究纳入加拿大 multicenter 队列中 87 例特发性炎性肌病(IIM)患者,采用捕获免疫分析检测基线血清可溶性 SIGLEC1(scSIGLEC1)水平。结果显示,较高的 scSIGLEC1 水平可区分医生整体活动度(PGA)评估的活动期与非活动期,并与皮肤、骨骼和胃肠道系统活动度及 1 年随访时较低的 TIS 评分相关。scSIGLEC1 评估疾病活动度的 ROC AUC 为 0.74,与 MYOACT 相当且优于肌酸激酶。

要点

  • scSIGLEC1可区分IIM整体疾病活动期与非活动期。
  • scSIGLEC1与皮肤、骨骼、胃肠道系统活动度相关。
  • scSIGLEC1评估活动度的ROC AUC为0.74,优于肌酸激酶。

核心结论

  • scSIGLEC1是监测IIM整体疾病活动度及皮肤、肌肉骨骼和胃肠道系统活动度的有前景的生物标志物。

研究设计与样本

  • 加拿大 multicenter IIM 队列研究,纳入 87 例有生物样本库血清和基线及 1 年随访临床数据的 IIM 患者。
  • 采用捕获免疫分析检测基线血清 scSIGLEC1 水平,并与 PGA、TIS 及 MYOACT 六个器官系统的 VAS 评分进行关联分析。

主要发现

  • 87 例 IIM 患者中女性占 67.8%,平均年龄 54.4±14.3 岁。
  • PGA 评估的活动期与非活动期患者 scSIGLEC1 水平差异为 2.7 ng/ml(95%CI 0.7-4.8)。
  • 有皮肤活动度者 scSIGLEC1 较无皮肤活动度者高 1.7 ng/ml(95%CI 0.1-3.4),有骨骼活动度者高 2.0 ng/ml(95%CI 0.1-3.9),有胃肠道活动度者高 2.2 ng/ml(95%CI 0.5-3.9)。
  • 较高的 scSIGLEC1 水平与 1 年随访时较低的 TIS 评分相关。

关键数值与推荐

  • scSIGLEC1 评估疾病活动度的 ROC AUC 为 0.74(95%CI 0.61-0.86),与 MYOACT 性能相当,优于肌酸激酶。
  • PGA 活动期与非活动期 scSIGLEC1 差异为 2.7 ng/ml(95%CI 0.7-4.8)。

临床怎么用

  • 可将血清 scSIGLEC1 作为 IIM 疾病活动度监测的候选生物标志物,尤其关注皮肤、肌肉骨骼和胃肠道系统受累。
  • scSIGLEC1 在评估疾病活动度方面与 MYOACT 相当且优于肌酸激酶,可作为辅助评估工具。

局限性

  • 研究为单队列观察性设计,样本量 87 例,需外部验证。
  • 仅检测基线 scSIGLEC1 水平,未报告纵向动态变化数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate soluble circulating sialic acid-binding Ig-like lectin 1 (scSIGLEC1), a surrogate biomarker for type I IFN, as a novel biomarker for idiopathic inflammatory myopathies (IIM) disease activity. METHODS: Patients enrolled in a Canadian multicentre cohort of IIM patients with biobanked serum samples and clinical data at baseline and 1-year follow-up were included. Serum scSIGLEC1 levels at baseline were tested using a capture immunoassay and evaluated in relation to disease activity, defined using patients' Physician Global Activity (PGA) scores, Total Improvement Scores (TIS) and visual analogue scale scores for the six organ systems included in the Myositis Disease Activity Assessment Visual Analogue Scales (MYOACT): constitutional, cutaneous, skeletal, gastrointestinal, pulmonary and cardiovascular. Performance of scSIGLEC1, MYOACT and creatine kinase to assess disease activity were compared [area under the receiver operating characteristic curve (ROC AUC)]. RESULTS: A total of 87 IIM patients (67.8% female, mean age 54.4 ± 14.3 years) were included. Higher scSIGLEC1 levels differentiated between active and inactive disease on the PGA (difference 2.7 ng/ml; 95% CI 0.7-4.8). Higher scSIGLEC1 levels were found among patients with cutaneous (difference 1.7 ng/ml; 95% CI 0.1-3.4), skeletal (difference 2.0 ng/ml; 95% CI 0.1-3.9) and gastrointestinal (difference 2.2 ng/ml; 95% CI 0.5-3.9) disease activity compared with patients without disease activity in these extramuscular organs, and were associated with lower TIS scores at 1-year follow-up. scSIGLEC1 levels (ROC AUC 0.74; 95% CI 0.61-0.86) matched MYOACT performance and outperformed creatine kinase in assessing disease activity. CONCLUSION: scSIGLEC1 levels are a promising biomarker for monitoring overall IIM disease activity, as well as activity involving the cutaneous, musculoskeletal and gastrointestinal systems.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Barreth N, Leclair V, Hudson M, et al. Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2026. PMID: 41872012. doi:10.1093/rheumatology/keag139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。